Lipitas Gold 75mg/20mg/75mg Capsule is a combination medication containing Aspirin 75mg, Rosuvastatin 20mg, and Clopidogrel 75mg, indicated for the prevention of cardiovascular events in patients at high risk of atherosclerotic cardiovascular disease (ASCVD). Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 production and platelet aggregation. Clopidogrel, a P2Y12 receptor antagonist, further inhibits platelet activation and aggregation, providing synergistic antithrombotic effects when combined with aspirin. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and exerts pleiotropic effects including plaque stabilization and anti-inflammatory actions. This combination is particularly beneficial in secondary prevention post-myocardial infarction, stroke, or in patients with established peripheral arterial disease. Lipitas Gold should be administered under medical supervision with appropriate monitoring of lipid profiles, liver function, and bleeding parameters. Caution is advised in patients with active bleeding, hepatic impairment, or hypersensitivity to any components. The use of this combination therapy aims to reduce the risk of recurrent cardiovascular events by addressing multiple pathophysiological pathways involved in thrombosis and atherosclerosis. Patient adherence and regular follow-up are essential to optimize therapeutic outcomes and minimize adverse effects.